Mary Lou Smith and colleagues at the Research Advocacy Network recently explored how well patients with early-stage breast cancer understand risk of recurrence
This randomized phase II trial aims to establish which agent, infliximab versus intravenous immunoglobulin, may lead to greatest benefit as pneumonitis treatment for patients receiving PD-1/PD-L1 therapy